儿童实体器官移植后EB病毒相关淋巴组织增生性疾病诊疗进展  

Progress in diagnosis and treatment of Epstein-Barr virus associated lymphoproliferative disease after solid organ transplantation in children

作　　者：赵金城 高怡瑾[1] Zhao Jincheng;Gao Yijin(Department of Hematology and Oncology,Shanghai Children′s Medical Center Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属上海儿童医学中心血液肿瘤科,200127

出　　处：《国际儿科学杂志》2022年第12期815-818,共4页International Journal of Pediatrics

摘　　要：移植后淋巴组织增生性疾病(post-transplant lymphoproliferative disease,PTLD)是儿童实体脏器移植(solid organ transplantation,SOT)后最严重的并发症之一,移植后的医源性免疫抑制和感染EB病毒是PTLD早期发病的主要原因。该病的诊断依靠病理,主要分为早期病变、单形性PTLD、多形性PTLD和霍奇金淋巴瘤型PTLD。治疗方法包括减少免疫抑制剂剂量、利妥昔单抗、化学治疗、放射治疗或外科手术等。不同的病理类型是选择化学治疗方案的主要依据。该文对PTLD的诊断及治疗的研究进展进行综述。Post transplant lymphoproliferative disease(PTLD)is one of the most serious malignant complication in children after solid organ transplantation.Immunosuppression after transplantation and Epstein-Barr virus infection are the two main reasons for the onset of PTLD.The diagnosis of the disease depends on pathology,which includes early lesions,monomorphic PTLD,polymorphic PTLD and Hodgkin′s lymphoma PTLD.The treatment includes reduction in immunosuppression,rituximab,chemotherapy,radiotherapy and surgery,etc.The selection of chemotherapy mainly depends on pathology.The advance in the management of PTLD will be reviewed in the manuscript.

关 键 词：儿童 移植后淋巴组织增生性疾病 EB病毒 实体器官移植 

分 类 号：R726.5[医药卫生—儿科]